Remission and low disease activity are associated with lower healthcare costs: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Megan R W BarberManuel Francisco Ugarte-GilJohn G HanlyMurray B UrowitzYvan St-PierreCaroline GordonSang-Cheol BaeJuanita Romero-DiazJorge Sanchez-GuerreroSasha BernatskyDaniel J WallaceDavid Alan IsenbergAnisur RahmanJoan T MerrillPaul R FortinDafna D GladmanIan N BruceMichelle A PetriEllen M GinzlerMary Anne DooleyRosalind Ramsey-GoldmanSusan ManziAndreas JönsenRonald F Van VollenhovenCynthia AranowMeggan MackayGuillermo Ruiz-IrastorzaS Sam LimMurat InançKenneth C KalunianSøren JacobsenChristine A PeschkenDiane L KamenAnca AskanaseBernardo A Pons-EstelFrancesca S CardwellGraciela S AlarconAnn Elaine ClarkePublished in: Annals of the rheumatic diseases (2024)
Our data suggest that systemic lupus erythematosus patients who achieve remission, both off and on-therapy, and reductions in disease activity incur lower costs than those experiencing persistent disease activity.